MICHAEL G UZMANN
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism LAS VEGAS, NV NPI 1265622260
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism NV Novo Nordisk AS All categories
General Payments — all program years on this page
$59,133.62
- Category: General Payments
- Program years: PY2018–2024
- Record count: 838
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $11,165.38 across 161 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $4,681.88 | 156 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,568.50 | 4 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,915.00 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $4,810.33 | 28 |
| DEXCOM, INC. | $2,641.09 | 22 |
| Insulet Corporation | $838.49 | 31 |
| Abbott Laboratories | $505.02 | 36 |
| BETA BIONICS, INC. | $353.91 | 3 |
| MannKind Corporation | $282.14 | 2 |
| Embecta Corp. | $267.92 | 3 |
| Medtronic, Inc. | $257.64 | 2 |
| Lilly USA, LLC | $245.43 | 3 |
| ABBVIE INC. | $206.75 | 12 |
| Xeris Pharmaceuticals, Inc. | $170.53 | 11 |
| Corcept Therapeutics | $159.18 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $145.92 | 1 |
| SANOFI-AVENTIS U.S. LLC | $143.81 | 3 |
| Tandem Diabetes Care, Inc. | $109.47 | 1 |
| IBSA Pharma Inc. | $27.75 | 2 |
By program year
Records — PY2024 (161)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.